These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10557569)

  • 21. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
    Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of repeated measurements with dropouts among Alzheimer's disease patients using summary measures and meta-analysis.
    Talwalker S
    J Biopharm Stat; 1996 Mar; 6(1):49-58. PubMed ID: 8838778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerance to tacrine, arterial hypotension and leuko-araiosis in Alzheimer's disease.
    Lebert F; Mouly C; Pasquier F
    Age Ageing; 1998 Sep; 27(5):654. PubMed ID: 12675108
    [No Abstract]   [Full Text] [Related]  

  • 24. Convulsive effects of tacrine.
    Lebert F; Hasenbroekx C; Pasquier F; Petit H
    Lancet; 1996 May; 347(9011):1339-40. PubMed ID: 8622541
    [No Abstract]   [Full Text] [Related]  

  • 25. [Tacrine: progress in treatment of Alzheimer's disease?].
    Kurz A; Marquard R; Mösch D
    Z Gerontol Geriatr; 1995; 28(3):163-8. PubMed ID: 7664190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The therapeutic potential of tacrine.
    Kurz A
    J Neural Transm Suppl; 1998; 54():295-9. PubMed ID: 9850938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical study of patients with Alzheimer's disease under treatment with tacrine].
    García-López MT; Guardado-Santervás P
    Rev Neurol; 2001 Feb 16-28; 32(4):394-7. PubMed ID: 11398762
    [No Abstract]   [Full Text] [Related]  

  • 28. Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.
    Lou G; Montgomery PR; Sitar DS
    J Psychiatry Neurosci; 1996 Nov; 21(5):334-9. PubMed ID: 8973053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term treatment of Alzheimer's disease: followup of a cohort of 255 patients treated with lacrine for four years].
    Michel BF; Estadieu MC; Gueriot C; Berthezène P; Allain H; Bongrand MC; Bonnefoy B; Bourrin JC; Chaix L; Graa K; Lejeune A; Messana M; Pras P; Ribiere J; Rihet P; Timon-David P; Tintignac A; Vincent S; Verdier JM; Gastaut JL
    Rev Neurol (Paris); 2001 Nov; 157(11 Pt 1):1365-75. PubMed ID: 11924005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrine. A cause of fatal hepatotoxicity?
    Blackard WG; Sood GK; Crowe DR; Fallon MB
    J Clin Gastroenterol; 1998 Jan; 26(1):57-9. PubMed ID: 9492866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tacrine in Alzheimer's disease].
    López de Munain A
    Rev Neurol; 1997 Jul; 25 Suppl 1():S70-2. PubMed ID: 9280671
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study.
    Kaufer DI; Cummings JL; Christine D
    J Geriatr Psychiatry Neurol; 1996 Jan; 9(1):1-6. PubMed ID: 8679057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrine for Alzheimer's disease.
    Med Lett Drugs Ther; 1993 Sep; 35(905):87-8. PubMed ID: 8361451
    [No Abstract]   [Full Text] [Related]  

  • 34. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
    Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L;
    Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic trials in Alzheimer's disease.
    Whitehouse PJ; Voci J
    Curr Opin Neurol; 1995 Aug; 8(4):275-8. PubMed ID: 7582042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity.
    Simon T; Becquemont L; Mary-Krause M; de Waziers I; Beaune P; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 2000 Apr; 67(4):432-7. PubMed ID: 10801254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tacrine in the treatment of Alzheimer's disease].
    Weinstein HC; Teunisse S; van Gool WA; van Crevel H
    Ned Tijdschr Geneeskd; 1991 Aug; 135(35):1575-7. PubMed ID: 1922487
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease.
    Kumar V; Becker RE
    Int J Clin Pharmacol Ther Toxicol; 1989 Oct; 27(10):478-85. PubMed ID: 2684868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Memantine (Ebixa) in clinical practice - results of an observational study.
    Calabrese P; Essner U; Forstl H
    Dement Geriatr Cogn Disord; 2007; 24(2):111-7. PubMed ID: 17622714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.
    Watkins PB; Zimmerman HJ; Knapp MJ; Gracon SI; Lewis KW
    JAMA; 1994 Apr; 271(13):992-8. PubMed ID: 8139084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.